Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

rials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments involving its product candidates and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2007 and Anadys' most recent Form 10-Q. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Condensed Consolidated Financial Statements

Anadys Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(In thousands except per share amounts)

(Unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

Revenues $-- $21,489 $-- $23,892

Operating expenses

Research and development(1) 7,581 7,602 19,091 21,275

General and administrative 2,084 2,444 6,104 6,844

Total operating expenses (2) 9,665 10,046 25,195 28,119

Interest income and other, net 316 864 1,311 2,855

Net (loss) income (2) $(9,349) $12,307 $(23,884) $(1,372)

Net (loss) income per share,

basic and diluted (2) $(0.32) $0.43 $(0.83) $(0.05)

Share used in calculating net

(loss) income per share,

basic and diluted
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 Silicon Valley Electronic Data Capture ... RPM Alliance , provider of clinical research and data ... latest addition to its CRO Partnership Program, Clinovo expands ... to India. , “We have found Clinovo’s ClinCapture ... EDC platform which is both user friendly and easy ...
(Date:11/26/2014)... 26, 2014 SoundConnect , an ... proud to announce that Darren Suders has joined the ... Darren will drive the partner program through ... , Darren brings more than 10-years of ... roles in channel operations, from policy development, to partner ...
(Date:11/26/2014)... , 25 novembre 2014 /PRNewswrie/ -- Theravalues Corporation ... il mercato europeo in occasione di Hi Europe 2014 ... ). Si tratta della curcumina con la ... amorfa (senza cristalli) e ingredienti approvati dalle norme europee. ... nella spezia della pianta curcumina ( Curcuma longa ) ...
(Date:11/24/2014)... Belgium , Nov. 24, 2014 ... focused on developing diagnostic tests for cancer and other conditions, ... will be presented at the Science for Business BioWin Day ... Belgium . The data come from VolitionRx,s lung cancer ... Pneumology department of the Centre Hospitalier Universitaire (CHU) de Liege ...
Breaking Biology Technology:RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2SoundConnect Appoints Director of Channel Development & Sales 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6
... young company with a preventive solution to identity theft took ... Burrill Technology Business Plan Competition, but if area investors want ... act quickly. , , Din and Newport stand in ... Khaja M. Din, president IPIC (Internet Privacy & ...
... of capturing 10 percent of the stem cell technology market ... directing the Department of Commerce to spend at least $5 ... companies to Wisconsin. , ,Doyle said the executive order, signed ... to stem cell research. Proponents of stem cell research cite ...
... and services to the financial and health-benefits industries, said ... to $1.1 billion. , ,Net income was $116 million, ... in the first quarter of 2005 on $973 million ... included repurchasing 5.4 million shares of common stock and ...
Cached Biology Technology:Winner of Burrill competition courted by North Carolina investors 2Winner of Burrill competition courted by North Carolina investors 3Doyle authorizes $5 million to woo stem cell companies 2
(Date:11/4/2014)... University of Utah engineers developed the first room-temperature fuel ... electricity without needing to ignite the fuel. These new ... off-grid power and sensors. , A study of the ... Society journal ACS Catalysis . , Fuel cells ... a fuel and an oxygen-rich source such as air. ...
(Date:11/4/2014)... – Temple University School of Medicine announced today ... an initiative funded by the Bill & Melinda ... of Obstetrics, Gynecology and Reproductive Sciences; and Vice ... University School of Medicine will pursue an innovative ... Blood Biomarkers to Assess Fetal Neurodevelopment.", Grand Challenges ...
(Date:11/4/2014)... A newly published research study examining only marketing ... of fast food restaurants has found that the ... disproportionately exposed to such marketing tactics. , Authored ... her colleagues, the study is the first to ... interior and exterior of fast food restaurants and ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Temple University School of Medicine receives Grand Challenges Explorations grant 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3
... during pregnancy can have serious consequences for the foetal brain. ... by vitamin C supplements after birth. This is shown through ... the scientific journal PLOS ONE . Population studies ... the developed world suffer from vitamin C deficiency. Therefore, pregnant ...
... PHILADELPHIA Passing one,s genes on to the next generation ... that the body would work to ensure that the genes ... New research by biologists at the University of ... the body does exactly that. This protective role is fulfilled ...
... that can be injected into the body, carrying drugs or ... types of disease, including cancer. However, these injectable gels don,t ... MIT chemical engineers have now designed an injectable gel that ... network that makes the gel much more durable, allowing it ...
Cached Biology News:Fetus suffers when mother lacks vitamin C 2A class of RNA molecules protects germ cells from damage, Penn vet researchers show 2A class of RNA molecules protects germ cells from damage, Penn vet researchers show 3New injectable gels toughen up after entering the body 2
... whose sequence is from the C-terminal end of the mouse retinoic acid ... acids 429 to 448 of RAR*. The sequence of PEP-005 is ... S - P - S - S - V - E - ... S - P - L - L - Q (The N-terminal ...
... Kit with Medium High quality ready-to-use cryopreserved ... base medium for growth and lineage commitment. ... generated from E18 fetal rat brain in ... mixture of in vitro stem/progenitor cells, neurons, ...
... for the use of small interfering RNA ... the RNA interference (RNAi) pathway have generated ... biology fields. siRNA for experimental use can ... enzymatically, and then transfected into the target ...
... for the use of small interfering RNA ... the RNA interference,(RNAi) pathway have generated tremendous ... fields. siRNA for experimental use can be,synthesized ... then transfected into the target cells in ...
Biology Products: